Kornimate/medical-research-clean huggingface dataset:
national mobile asthma management system-e project

Conditions: Asthma

Summary: bronchial asthma is a heterogeneous disease characterized by chronic airway inflammation, which is a common and frequently occurring disease in the world, and has resulted in a sustained increase of social and economic burden. however, several studies suggest, lots of asthma patients did not get their asthma controlled. the investigators study showed that in china only 28.7% of asthma patients achieve asthma controlled during 2007-2008. in recent years, application softwares of mobile-phones for asthma have gradually increased, studies suggested that application of these application softwares can make treatment more standard, reduce asthma attacks, help patients to control their asthma, improve adherence and these application softwares also show many other advantages. this study is a prospective, multi center, randomized, controlled study, aims to evaluate the efficacy of application softwares in asthma patients, provide a new tool to asthma management.


Eligibility criteria:
inclusion criteria: 1.18 years of age or older, having been resided in the same city during the study; 2.a history of at least 3 months of diagnosed asthma based on the criteria established by gina 2016; need to be on medication containing ics or ics/laba 3.asthma out patients with act scores﹤20 and mars - a mean score \< 4.5 ; 4.owning and being able to use smart phone that the corresponding software can be successfully installed; 5.subjects who are willing to participate in the study and sign the informed consent. exclusion criteria: 1. unable to communicate properly because of visual impairment, hearing impairment and language barrier, or with mental illness or psychological problems; 2. have a history of tracheal intubation or mechanical ventilation as a result of acute asthma attack; 3. have respiratory tract infection within the prior 4 weeks; history of thoracic surgery; with comorbidities such as other/structural lung diseases (copd, bronchiectasis, lung cancer, et al); heart disease; kidney or autoimmunity disease; or other conditions that could potentially effect asthma control or asthma disease status by investigator's medical opinion. 4. women with pregnancy, or planned pregnancy within one year.

Keywords: asthma m-health asthma control self-management
the development and study of a 3d-printed model for surgical planning of lung cancer with realistic subsegmental boundaries and complete tissue structures

Conditions: Lung Cancer

Summary: this project focuses on the development of a precision multi-organ surgical planning model aided by artificial intelligence (ai), computer-aided design (cad), multi-material 3d printing, and multimodal 3d modeling. the integration of these advanced technologies aims to enhance the accuracy and efficiency of preoperative planning for complex surgical procedures involving multiple organs. by leveraging ai and cad, the project seeks to create detailed, patient-specific 3d models that incorporate various imaging modalities. these models will be used to guide multi-material 3d printing, producing highly accurate replicas of anatomical structures. the ultimate goal is to improve surgical outcomes by providing surgeons with precise and comprehensive tools for planning and executing intricate surgeries.


Eligibility criteria:
inclusion criteria: * patients diagnosed with lung cancer * complete clinical case data; * all patients underwent surgical treatment; * voluntarily participate in the study and sign the informed consent. exclusion criteria: * severe comorbidities, such as uncontrolled heart disease or diabetes * history of major surgeries or other interventions * unwillingness to participate in the study
the combine study: the ckd optimal management with binders and nicotinamide

Conditions: Chronic Kidney Disease

Summary: the combine clinical trial is a pilot study evaluating the effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor 23 (fgf23) in patients with chronic kidney disease (ckd) stages 3-4.


Eligibility criteria:
inclusion criteria: 1. patients with estimated glomerular filtration rate (egfr) 20-45 ml/min/1.73m2 2. age 18-85 years 3. serum phosphate ≥ 2.8 mg/dl 4. platelet count ≥ 125,000/mm3 5. able to provide consent 6. able to travel to study visits 7. able to eat at least two meals a day 8. in the opinion of the site investigator, willing and able to follow the study treatment regimen and comply with the site investigator's recommendations. exclusion criteria: 1. history of allergic reaction to nicotinamide, niacin (excluding flushing), multivitamin preparations, or lanthanum carbonate 2. liver disease, defined as known cirrhosis by imaging or physician diagnosis, documented alcohol use \> 14 drinks/week, or aspartate aminotransferase (ast), alanine aminotransferase (alt), alkaline phosphatase, or total bilirubin concentrations \> 2 times the upper limit of the local laboratory reference range 3. creatine kinase (ck) concentrations \> 2 times the upper limit of the local laboratory reference range 4. major hemorrhagic event within the past six months requiring in-patient admission 5. blood or platelet transfusion within the past six months 6. secondary hyperparathyroidism (pth \> 5 times the upper limit of normal range for the laboratory) or currently taking cinacalcet (sensipar) 7. current, clinically significant malabsorption, as determined at the discretion of the site investigator 8. anemia (screening hg \< 9.0 g/dl) 9. serum albumin \< 2.5 mg/dl 10. anticipated initiation of dialysis or kidney transplantation within 12 months as assessed by and at the discretion of the site investigator. 11. use of immunosuppressive medications (stable oral steroids ≤ 10 mg of prednisone/day or inhaled steroids are exempted) 12. in the opinion of the site investigator, active abuse of alcohol or drugs 13. recent (within the last 14 days) initiation or change in dose of treatment with 1,25 (oh)2 vitamin d or active vitamin d analogues (paricalcitol or hectorol). patients on stable doses of these agents initiated more than 14 days prior to screening are eligible to participate. 14. current or recent treatment (within the last 14 days) with phosphate binder or niacin/nicotinamide \> 100 mg/day 15. current participation in another clinical trial or other interventional research 16. currently taking investigational drugs 17. institutionalized individuals, including prisoners and nursing home residents 18. malignancy requiring therapy within 2 years (basal or squamous cell skin carcinoma and localized prostate cancer are exempted) -
multicentric study an endoscopic treatment of digestive neoplasia by submucosal dissection evaluation of a new water jet system

Conditions: Stomach Neoplasm; Intestinal Neoplasm; Rectal Neoplasm

Summary: safety evaluation of endoscopic sub-mucosal dissection with nestis enki2 system. this system is a new water jet system which allows to perform endoscopic submucosal dissection with a bifunctional catheter (injection and cutting).

evaluation of the ability of this system to have a complete resection of superficial tumors of the digestive tract (that is to say a resection with free lateral and deep margins without residual tumor tissue) evaluation of the ability of such system to inject a viscous macromolecular solution of glycerol (glycerol mix: glycerol 10 %, fructose 5 %, saline solution 0.9%)(27. fujishiro m, yahagi n, kashimura k, et al. comparison of various submucosal injection solutions for maintaining mucosal elevation during endoscopic mucosal resection. endoscopy. 2004;36:579-583.)

Eligibility criteria:
inclusion criteria: * over 18 years old * patients agreed with the study * score asa 1 or 2 * patient recorded in a social safety organism * patients presenting with superficial lesions with an endoscopic indication of resection exclusion criteria: * under 18 years old * patients not agreed with the study * pregnant women * patient included in an another study * medical treatments (radiotherapy, surgery endoscopis treatements) before the intervention * coagulation disorders * score asa over 3 * patients with another neoplasic lesion

Keywords: oesophagus stomach intestine rectum
efficacy of a face to face versus a remote physiotherapy instruction session about pelvic floor in women with urinary incontinence

Conditions: Urinary Incontinence

Summary: the purpose of this study is to assess and to compare the efficacy of a face to face versus a remote physiotherapy instruction session about pelvic floor muscle (pfm) function, including teaching women how to contract their pfm and how to perceive a correct pfm contraction. study participants will be randomly assigned to participate in one of the three study groups: group 1 will receive face to face instructions, group 2 will receive real time remote instructions and group 3 will not receive any instruction. the primary outcome measure is pfm function assessed using the modified oxford scale.


Eligibility criteria:
inclusion criteria: * women who are not able to contract their pfm (≤ 2 of modified oxford scale); * cognitive ability, hearing and visual acuity preserved (through 10-point cognitive screener and snellen test, respectively); * non-neurogenic ui; * no history of neurological disorders; * no symptoms of a vaginal or urinary tract infection; * pelvic organ prolapse ≤2 (according to the baden and walker scale); * who have not already been instructed on how to perform pfm contraction or who is not already performing pfm training; * no suspected or confirmed pregnancy. exclusion criteria: * who have intolerance to physical examination, or latex allergy; * who withdraws from participating in the study.
the efficacy of myofascial release at the cervicothoracic region in patients with rotator cuff repairs

Conditions: Rotator Cuff Tears

Summary: this study was conducted the patients with rotator cuff tears who underwent rotator cuff repair surger.the patients were randomly divided into 2 groups and a total of 20 subjects were randomized in a single block order using randomallocation software 1.0.0 by simple randomization.all evaluation and treatment was done by the same physiotherapist.the first group was included in the traditional treatment program after rotator cuff repair, while the second group was included in the myofascial release program, 2 sessions a week between the 4th and 7th weeks, in addition to the traditional treatment.

patients in the 2 groups undergoing rc repair were also included in a similar physiotherapy program.immobilization with a sling was made for 4-6 weeks after surgery. in addition to physiotherapy in group 2, myofascial release therapy was applied to the upper trapezius, sternocloidomastoideus, pectoral muscles (major, minor) 2 days a week between the 4th and 7th weeks after surgery, in addition to the conventional treatment. myofascial treatment took 30-45 minutes per session.

Eligibility criteria:
inclusion criteria: * aged betweeen 18-65 * diagnosed with rc tear exclusion criteria: * wanting to leave the study * not participating in assessments and/or treatments * presence of massive tears * accompanying nerve injuries, * presence of labral lesion, * diagnosed psychological problems, * central nervous system problems * those with any rheumatological and orthopedic diseases * individuals who have had previous surgery on the same shoulder

Keywords: myofascial release rotator cuff tears physiotherapy rotator cuff repair
lymphoedema among persons with head- and neck cancer

Conditions: Cancer of Head and Neck

Summary: lymphedema in the head and neck area is common after treatment for head and neck cancer. the aim of the research project is: • to assess the prevalence of lymphedema in patients with head and neck cancer (hnc) by measuring the amount of tissue water in the head and neck area before and after different kinds of cancer treatment, and to evaluate the quality of life before and after cancer treatment.

measurement of tissue water is performed with a device (moisturemeterd) see appendix 1. in addition, the neck circumference will be assessed with a measuring tape, according to purcell (9), see appendix 2. the measurement will be completed by agneta hagren, or one of her colleagues, with specific education. the assessments will be performed before treatment begins as part of the clinical routine (baseline), and at 3 months, and 9 months after treatment completion. each participant will respond to quality-of-life qlq-c30 and qlq h\&n35 questionnaires, appendix 3 and 4, at the same time points as the measurements of tissue water. ratings of physical activity according to frändin and grimby will also be performed (23). the questionnaires will be sent home to the patients before the time for follow-up. a modified lyqli questionnaire will be given to all patients with lymphedema and filled out at 9 months after treatment completion, appendix 5. post-treatment measurements +/- four weeks of the dedicated time point will be considered appropriate. discontinuing participation in the trial will be on: 1. patient request 2. locoregional tumor progression or failure during the study period. for example, residual neck tumor requiring neck dissection after (c)rt for opc 3. locoregional deep infection i.e., suspected abscess at the scheduled time points for measurements. any interventional therapy for lymphedema during the follow-up is not cause for exclusion but will be registered.

Eligibility criteria:
inclusion criteria: * biopsy or cytology confirmed hnc (all malignant types are accepted) from the oropharynx (opc), oral cavity (oc) or neck metastases from unknown primary cancer of the head and neck (cup). * tumour stage t1-4, n0-3. * planned for treatment with curative intent as recommended at the multidisciplinary tumour board. * age \>18 years. able to give informed consent exclusion criteria: * previous treatment of hnc or radiation to the head and neck area. * planned surgery that includes free tissue transfer or pedicled flaps in the neck (local facial pedicled flaps are accepted). * planned neck dissection involving less than three regions of the neck. * planned proton therapy. * pre-treatment surgery or botox injections in the tissue in the head and neck area. * pregnancy

Keywords: lymphoedema quality of life head and neck cancer treatment
alberta hip improvement project

Conditions: Arthroplasty, Replacement, Hip

Summary: a study to determine the effectiveness and safety of the use of metal-on-metal hip resurfacing (for example the birmingham hip) when compared to conventional total hip replacement.

this study is designed to provide orthopedic surgeons and decision makers with evidence-based health measures for patients that are treated by orthopedic surgeons for degenerative joint disease of the hip in alberta. this study is provincial initiative to determine whether new alternative hip bearing surfaces improve patient outcomes and/or decrease health resource utilization in patients with degenerative joint disease of the hip in alberta. the primary objective is to compare time to revision for patients receiving alternative hip bearing surfaces to patients receiving conventional total hip replacements. secondary objectives are to evaluate long-term safety; to evaluate costs; to determine if alternative hip bearing surfaces improve patient function; to develop evidence base guidelines for the implementation of alternative hip bearing surfaces in alberta; do develop a modal to assess other technologies and health advances; to develop an alberta hip registry

Eligibility criteria:
inclusion criteria: * documentation of djd of hip * patient at least 18 years * patient able to provide written consent * male under 65 years, female under 56 years * orthopedic surgeon has received appropriate training to implant an alternative device exclusion criteria: * renal failure (mom only) * child bearing potential (mom only) * inappropriate femoral anatomy, including evidence of osteoporosis * inflammatory arthritis (mom) * unwilling to consent

Keywords: prospective conventional therapy registry metal-on-metal ceramic-on-ceramic hip arthroplasty
the effect of glycemic control on malondialdehyde, glutathione peroxidase, glutathione and paraoxonase

Conditions: Type 2 Diabetes Mellitus; Chronic Periodontitis

Summary: the aim of this study was to investigate the impact of glycemic control on clinical periodontal status, levels of malondialdehyde (mda), glutathione peroxidase (gsh-px), reduced glutathione (gsh) and paraoxonase (pon) activity in gingival crevicular fluid (gcf) and blood samples of type 2 diabetes mellitus (t2dm) patients with chronic periodontitis (cp).

reactive oxygen species (ros) are products of normal cellular metabolism and play beneficial role in physiological functions. overproduction of ros and/or deficiency of enzymatic or non-enzymatic antioxidants, termed as oxidative stress, is involved in many pathological conditions such as diabetes mellitus (dm) and chronic periodontitis (cp). several researches revealed that dm, with many determinants such as level of glycemic control, stands as a strong risk factor for periodontal diseases. on the other side, periodontal diseases induce an elevated chronic inflammatory state and exacerbated insulin resistance. in the present study, the investigators examined the effect of glycemic control level on clinical periodontal status, levels of mda, gsh-px, gsh and pon activity in gingival crevicular fluid and blood samples of cp patients with t2dm.

Eligibility criteria:
inclusion criteria: * to present t2dm diagnosis by an endocrinologist for at least the past 5 years * diagnosis of cp was based on the clinical and radiographic criteria proposed by the 1999 world workshop for classification of periodontal diseases and conditions exclusion criteria: * pregnancy * lactation * current smoking or smoking within the past 2 years, periodontal therapy in the previous 6 months * antibiotic and/or antimicrobial therapies in the previous 3 months * existence of serious diabetic complications or any pathology such as haemoglobinopathy which would affect haemoglobin profile * diagnosis of another major medical pathology, middle or upper-level obesity according to who classification * current anti-hyperlipidemic therapy * non-t2dm patients with abnormal values of glucose and lipid metabolism parameters, major medical pathology and family history of dm

Keywords: diabetes mellitus chronic periodontitis malondialdehyde glutathione peroxidase paraoxonase
effects of hfnc on moderate and severe respiratory failure patients

Conditions: Respiratory Failure

Summary: respiratory failure is the danger for the patients admitted in icu, mechanical ventilation could save a lot of patients' life, however, it prolongs patients' icu stay and hospital stay. high flow nasal cannula (hfnc) has advantages of peep effects, reducing dead space, increasing eelv and improving comfort, and it has been used to treat respiratory failure patients. in recent study, hfnc could improve mortality of respiratory failure patients with p/f\<200mmhg in the subgroup. the investigators want to start a randomized controlled study to evaluate the effects of hfnc on the patients with respiratory failure.

just as the brief summary

Eligibility criteria:
inclusion criteria: 1. age\>18 years 2. patients met all four of the following criteria: * a respiratory rate of more than 25 breaths per minute, * a ratio of the partial pressure of arterial oxygen (pao2) to the fio2 of 300 mm hg or less while the patient was breathing oxygen at a flow rate of 10 liters per minute or more for at least 15 minutes, * a partial pressure of arterial carbon dioxide (paco2) not higher than 45 mmhg, and * an absence of clinical history of underlying chronic respiratory failure exclusion criteria: 1. paco2 of more than 45 mm hg 2. exacerbation of asthma or chronic respiratory failure 3. cardiogenic pulmonary edema 4. severe neutropenia 5. hemodynamic instability, use of vasopressors, 6. glasgow coma scale score of 12 points or less (on a scale from 3 to 15, with lower scores indicating reduced levels of consciousness) 7. contraindications to noninvasive ventilation 8. urgent need for endotracheal intubation, a do-not-intubate order, and a decision not to participate.

Keywords: hfnc respiratory failure intubation mortality
the aspirometer: a noninvasive tool for detecting aspiration aim 3

Conditions: Deglutition Disorders

Summary: this investigation evaluates the effectiveness of a device called the aspirometer, which uses high resolution cervical auscultation (hrca), in detecting when food or liquids enter the airway (aspiration) of the person swallowing, whether the person swallowing shows signs of aspiration (coughing) or not.

this aim of the project seeks to discriminate normal from abnormal airway protection and kinematic functions noninvasively via machine-learning analysis of aspirometer/hrca (high resolution cervical auscultation) signals, with similar accuracy as human judgment of vf. hypothesis: advanced data analytics can detect pathological airway protection in hrca signal signatures with 90% accuracy when compared to a human expert's airway protection ratings from vf images. analytical algorithms that can learn from data (e.g., bayes' learning) will be used to infer about the continuum of abnormal airway protection during swallowing.

Eligibility criteria:
inclusion criteria: - referred by an attending physician as an inpatient, for a modified barium swallow examination due to suspected dysphagia and aspiration exclusion criteria: * tracheostomy * pregnant * unable to follow verbal commands * anatomic disruption of head neck * radiation therapy to head or neck

Keywords: dysphagia artificial intelligence machine learning
iron deficiency anemia in twin pregnancies

Conditions: Anemia, Iron-Deficiency

Summary: all pregnant women with twin pregnancies were given oral iron according to the current recommended dose. blood routine and ferritin were monitored during pregnancy to understand the therapeutic effect of oral iron on iron deficiency anemia and iron deficiency in pregnant women with twin pregnancies

all pregnant women with twin pregnancies were given oral iron according to the current recommended dose. blood routine and ferritin were monitored every 2-4 weeks during pregnancy to understand the therapeutic effect of oral iron on iron deficiency anemia and iron deficiency in pregnant women with twin pregnancies.after delivery, we will test the neonatal ferritin and hemoglobin status. our aim was to investigate the effects of iron supplementation during twin pregnancy on maternal and neonatal ferritin and anemia.

Eligibility criteria:
inclusion criteria: * chinese * pregnant women with twin pregnancies exclusion criteria: * single pregnancy * types of anemia other than iron deficiency anemia